Mark Eisner Fibrogen Inc (FGEN) insider trading activity

Mark Eisner is EVP, Chief Medical Officer of FIBROGEN INC. Currently has a direct ownership of 159,917 shares of FGEN, which is worth approximately $76,760. The most recent transaction as insider was on Sep 06, 2023, when has been sold 1,860 shares (Common Stock) at a price of $0.96 per share, resulting in proceeds of $1,785. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 160K

0% 3M change

0% 12M change

Total Value Held $76,760

Mark Eisner Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 06 2023	SELL Payment of exercise price or tax liability	$1,785 $0.96 p/Share	1,860 Reduced 1.15%	159,917 Common Stock
Sep 01 2023	SELL Payment of exercise price or tax liability	$1,150 $1.06 p/Share	1,085 Reduced 0.67%	161,777 Common Stock
Jun 07 2023	SELL Open market or private sale	$34,795 $17.04 p/Share	2,042 Reduced 1.24%	162,862 Common Stock
Jun 02 2023	SELL Open market or private sale	$20,524 $18.83 p/Share	1,090 Reduced 0.66%	164,904 Common Stock
Apr 04 2023	SELL Open market or private sale	$172,437 $18.78 p/Share	9,182 Reduced 5.24%	165,994 Common Stock
Mar 10 2023	SELL Open market or private sale	$204,828 $20.2 p/Share	10,140 Reduced 5.47%	175,176 Common Stock
Mar 08 2023	SELL Open market or private sale	$155,801 $21.16 p/Share	7,363 Reduced 4.27%	165,133 Common Stock
Mar 08 2023	BUY Grant, award, or other acquisition	-	20,183 Added 9.82%	185,316 Common Stock
Mar 02 2023	SELL Open market or private sale	$25,959 $21.87 p/Share	1,187 Reduced 0.68%	172,496 Common Stock
Feb 21 2023	BUY Grant, award, or other acquisition	-	32,500 Added 15.76%	173,683 Common Stock
Dec 01 2022	SELL Payment of exercise price or tax liability	$16,303 $15.04 p/Share	1,084 Reduced 0.76%	141,183 Common Stock
Sep 30 2022	SELL Payment of exercise price or tax liability	$88,169 $13.01 p/Share	6,777 Reduced 4.55%	142,267 Common Stock
Sep 01 2022	SELL Payment of exercise price or tax liability	$9,896 $13.09 p/Share	756 Reduced 0.5%	149,044 Common Stock
Jun 01 2022	SELL Payment of exercise price or tax liability	$10,965 $9.61 p/Share	1,141 Reduced 0.76%	149,800 Common Stock
Mar 31 2022	SELL Payment of exercise price or tax liability	$77,433 $12.02 p/Share	6,442 Reduced 4.09%	150,941 Common Stock
Mar 01 2022	SELL Payment of exercise price or tax liability	$10,297 $13.62 p/Share	756 Reduced 0.48%	157,383 Common Stock
Feb 14 2022	BUY Grant, award, or other acquisition	-	60,000 Added 27.51%	158,139 Common Stock
Jan 03 2022	SELL Payment of exercise price or tax liability	$104,377 $14.82 p/Share	7,043 Reduced 6.7%	98,139 Common Stock
Dec 01 2021	SELL Payment of exercise price or tax liability	$54,876 $12.65 p/Share	4,338 Reduced 3.96%	105,182 Common Stock
Oct 04 2021	BUY Grant, award, or other acquisition	-	74,520 Added 40.49%	109,520 Common Stock
Dec 01 2020	BUY Grant, award, or other acquisition	-	35,000 Added 50.0%	35,000 Common Stock

Also insider at

VIR

Vir Biotechnology, Inc. Healthcare

EVP and Chief Medical Officer

Mark Eisner

EVP, Chief Medical Officer

San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells FGEN shares.

Notify only if

Value

Insider Trading

Get notified when an Fibrogen Inc insider buys or sells FGEN shares.

Notify only if

Operation

Value

Type

News

Receive news related to FIBROGEN INC

Track Activities on FGEN

Account